Research progress in DZNep in tumor therapy / 肿瘤
Tumor
;
(12): 938-943, 2016.
Artigo
em Chinês
| WPRIM
| ID: wpr-848604
ABSTRACT
Enhancer of zeste homolog 2 (EZH 2) is considered to be a novel oncogene in recent years. 3-Deazaneplanocin A (DZNep, an inhibitor of EZH2), has been intensively focused for its effect upon cancers by exerting potential anti-proliferative and pro-apoptotic effects via blocking the EZH2 pathway. As a new chromatin modification drug, growing evidence suggests that DZNep is involved in pathophysiological process of tumor cells, such as proliferation, apoptosis, invasion, metastasis and vascularization. DZNep may provide a new approach for the treatment of tumors. This review summarizes the research progress in DZNep in tumor therapy.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Tumor
Ano de publicação:
2016
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS